Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOMORROW: Nintedanib Phase 2 in IPF
NCT00514683Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2007
- Primary completion
- Jun 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial of nintedanib in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Rate of Decline in Forced Vital Capacity at 52 weeks. Started Aug 2007; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00514683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514683.